The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung

Human Pathology

Volumn 34, Issue 2, 2003, Pages 136-142

  Beasley, Mary Beth ^b   Lantuejoul, Sylvie ^b   Abbondanzo, Susan ^b   Chu, Wei Sing ^b   Hasleton, Philip S ^b   Travis, William D ^b   Brambilla, Elizabeth ^a  

^a Laboratoire de Pathologie Cellulaire   (France)

^b NONE

Author keywords

Cyclin D1; Neuroendocrine lung tumors; P16INK4; Rb pathway

Indexed keywords

CYCLIN D1; PROTEIN P16; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CELL CYCLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL;

EID: 0037330728     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2003.8     Document Type: Article

References (28)

1. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996
2. Resnitzky D, Gossen M, Bujard H, et al: Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14:1669-1679, 1994
3. Quelle DE, Ashmun RA, Shurtleff SA, et al: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7:1559-1571, 1993
4. Michalides R, van Veelen N, Hart A, et al: Overexpression of cyclin D1 correlates w with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 55:975-978, 1995
5. Brambilla E, Moro D, Gazzeri S, et al: Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 188:351-360, 1999
6. Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994
7. Lukas J, Parry D, Aagaard L, et al: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375:503-506, 1995
8. Kratzke RA, Greatens TM, Rubins JB, et al: Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 56: 3415-3420, 1996
9. Otterson GA, Kratzke RA, Coxon A, et al: Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wild-type Rb. Oncogene 9:3375-3378, 1994
10. Shapiro GI, Edwards CD, Kobzik L, et al: Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55:505-509, 1995
11. Kinoshita I, Dosaka-Akita H, Mishina T, et al: Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: Potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res 56:5557-5562, 1996
12. Sakaguchi M, Fujii Y, Hirabayashi H, et al: Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: An immunohistochemical study. Int J Cancer 65:442445, 1996
13. Betticher DC, Heighway J, Hasleton PS, et al: Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small cell lung cancer. Br J Cancer 73:294-300, 1996
14. Mate JL, Ariza A, Aracil C, et al: Cyclin D1 overexpression in non-small cell lung carcinoma: Correlation with Ki67 labelling index and poor cytoplasmic differentiation. J Pathol 180:395-399, 1996
15. Nishio M, Koshikawa T, Yatabe Y, et al: Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 3:1051-1058, 1997
16. Schauer IE, Siriwardana S, Langan TA, et al: Cyclin DI overexpression vs. retinoblastoma inactivation: Implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci U S A 91:7827-7831, 1994
17. Dosaka-Akita H, Cagle PT, Hiroumi H, et al: Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung. Cancer 88:550-556, 2000
18. Cagle PT, el-Naggar AK, Xu HJ, et al: Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications. Am J Pathol 150:393-400, 1997
19. Gouyer V, Gazzeri S, Bolon I, et al: Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am J Respir Cell Mol Biol 18:188-196, 1998
20. Yuan J, Knorr J, Altmannsberger M, et al: Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol 189:358-362, 1999
21. Travis WC, Corrin B, Shimosato Y, et al: Histological typing of lung and pleural tumours, in Sobin L (ed): International Histological Classification of Tumours. Geneva, Switzerland, World Health Organization, 1999
22. Gazzeri S, Gouyer V, Vour'ch C, et al: Mechanisms of p16INK4A inactivation in non-small-cell lung cancers. Oncogene 16:497-504, 1998
23. Gillett C, Fantl V, Smith R, et al: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812-1817, 1994
24. Onuki N, Wistuba, II, Travis WD, et al: Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 85:600-607, 1999
25. Gazzeri S, Della Valle V, Chaussade L, et al: The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res 58:3926-3931, 1998
26. Debelenko LV, Brambilla E, Aganval SK, et al: Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 6:2285-2290, 1997
27. Eymin B, Gazzeri S, Brambilla C, et al: I)istinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 20:1678-1687, 2001
28. Przygodzki RM, Finkelstein SD, Langer JC, et al: Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 148:1531-1541, 1996